Sanofi has joined GlaxoSmithKline in facing bribery allegations in China. According to a Chinese newspaper, the whistleblower says Sanofi paid 1.7 million yuan in bribes to 503 doctors around the country.
India's Ranbaxy Laboratories has been manufacturing drugs in Malaysia since before anyone was talking about emerging markets. Now, it is about ready to expand on that position with a second plant in the country.
GE Healthcare has bought Brazil's Omnimed, a producer of patient monitoring devices, part of the conglomerate's effort to increase its share of the Latin American market.
In another swipe at the intellectual property of drugmakers in emerging markets, China's State Intellectual Property Office (SIPO) has yanked the patent for Viread, saying it lacks novelty.
As the company's current scandal in China shows, Witty was caught somewhat flat-footed by problems there, and some investors wonder whether Witty's reforms have been rigorous enough.
Brazilian drugmaker Hypermarcas shows that market savvy pays, even when an economy hits the skids. Despite an unexpected lag in GDP growth, Hypermarcas posted a surprise profit for the second quarter. A sales surge helped swing the company into the black, with pharma sales alone up 13.3%.
Stryker's Kevin Lobo came aboard after the surprise ouster of Stephen MacMillan, and, in his first year at the helm of the Michigan device giant, the CEO has presided over a huge Chinese buyout, a lasting recall sting and expansions into new markets.
Big Pharma companies are fighting to stay out of the spotlight as authorities show up to visit them.
Because Sanofi has been investing heavily in emerging markets in recent years to help it offset revenue declines from patent expirations, a 2.3% crash in sales in those markets was a big surprise.
Baxter uncovered expense violations in July 2012 from a joint venture in China, which went undisclosed until the WSJ contacted it with an anonymous tipster's information that employees at the venture fabricated conferences as part of a bribery scheme.